natgillin/translations-raw huggingface dataset:
Eat glucose tablets or another high sugar snack, like sweets, biscuits or fruit juice (always carry glucose tablets or a high sugar snack, just in case).
Zaužijte tablete glukoze ali kakšen drug prigrizek, ki vsebuje veliko sladkorja, na primer bonbone, piškote ali sadni sok (za vsak primer vedno nosite s seboj tablete glukoze ali prigrizek z veliko vsebnostjo sladkorja).
Eat healthier food and try to avoid spicy and fatty foods and large meals late before bedtime.
Uživajte bolj zdravo hrano in se izogibajte začinjeni ter mastni hrani in velikim obrokom pred spanjem;
eat low-fat, high protein foods instead of fatty or spicy foods
namesto mastne ali začinjene hrane uživajte malo mastno hrano, bogato z beljakovinami,
Eat lower-fat meals to help manage these effects.
Da bo možnost pojava teh učinkov na črevesje zmanjšana, uživajte hrano z manj maščobami.
Eat lower-fat meals to reduce the chance of diet-related treatment effects (see section 4).
Uživajte hrano, ki vsebuje manj maščob, da bi tako zmanjšali možnost neželenih učinkov (glejte poglavje 4).
eat more than usual
jeste več kot ponavadi,
Eat slowly
Jejte počasi.
Eat slowly and eat smaller portions.
jejte počasi in uživajte manjše obroke;
eat too little or miss a meal use too much Xultophy.
premalo jeste ali izpustite obrok, uporabite prevelik odmerek zdravila Xultophy.
Eat too little or miss a meal.
premalo jeste ali izpustite obrok,
Eat too little or miss a meal.
če premalo jeste ali izpustite obrok,
eating a lot more than your diet allows; or fever, infection or emotional stress.
pojedli ste veliko več, kot predpisuje vaša dieta; ali imate zvišano telesno temperaturo, okužbo ali čustvene obremenitve.
Eating disorders including anorexia
motnje prehranjevanja vključno z anoreksijo
eating disorders, not eating enough, leading to weight loss
motnje hranjenja, nezadostno uživanje hrane, kar povzroči hujšanje
eating disorders, not eating enough, leading to weight loss
motnje hranjenja, nezadostno uživanje hrane, kar povzroči hujšanje,
eating disorders: not eating enough, leading to weight loss
motnje hranjenja, nezadostno uživanje hrane, kar povzroči hujšanje,
Eating more than usual
Jeste vec kot ponavadi.
Eating salty food or drinking fluids before or after taking Norvir oral solution can help clear the aftertaste from your mouth.
Če pred jemanjem peroralne raztopine Norvir pojeste kaj slanega ali popijete nekaj tekočine, lahko to pomaga odpraviti priokus zdravila v ustih.
Eating salty foods or drinking fluids before or after taking Norvir oral solution may help clear the aftertaste from your mouth.
Če pred ali po jemanju peroralne raztopine Norvir pojeste kaj slanega ali popijete nekaj tekočine, lahko to pomaga odpraviti priokus zdravila v ustih.
Ebastine
Ebastin
Ebilfumin 30 mg [for the outer carton only]
Ebilfumin 30 mg (samo za škatlo)
Ebilfumin 30 mg hard capsules Oseltamivir
Ebilfumin 30 mg trde kapsule oseltamivir
Ebilfumin 45 mg [for the outer carton only]
Ebilfumin 45 mg (samo za škatlo)
Ebilfumin 75 mg [for the outer carton only]
Ebilfumin 75 mg (samo za škatlo)
Ebilfumin can also be prescribed for adults, adolescents, children and infants above 1 year of age for preventing flu, on a case-by-case basis – for instance, if you have been in contact with someone who has flu.
Zdravilo Ebilfumin se lahko predpiše odraslim, mladostnikom, otrokom in dojenčkom, starejšim od 1 leta, tudi za preprečevanje gripe, odvisno od primera do primera – na primer, če ste bili v stiku z osebo, ki ima gripo.
Ebilfumin has no effect on your ability to drive or use machines.
Zdravilo Ebilfumin nima vpliva na vašo sposobnost vožnje in upravljanja s stroji.
Ebilfumin is a ‘generic medicine’.
Zdravilo Ebilfumin je „generično zdravilo“.
Ebilfumin is an antiviral medicine that contains the active substance oseltamivir.
Ebilfumin je zdravilo, ki vsebuje zdravilno učinkovino oseltamivir.
Ebilfumin is available as capsules (30, 45 and 75 mg) and can only be obtained with a prescription.
Zdravilo Ebilfumin je na voljo v obliki kapsul (30 mg, 45 mg in 75 mg) in se izdaja le na recept.
Ebilfumin is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2).
Zdravilo Ebilfumin je indicirano za preprečevanje gripe po izpostavljenosti virusu pri dojenčkih, mlajših od 1 leta, med izbruhom pandemije gripe (glejte poglavje 5.2).
Ebilfumin is indicated in adults and children including full-term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community.
Zdravilo Ebilfumin je indicirano pri odraslih in otrocih, vključno z donošenimi novorojenčki, ki imajo simptome, značilne za gripo, ko je virus influence prisoten v okolici.
Ebilfumin is used for adults, adolescents, children and infants (including full-term newborn babies) for treating flu (influenza).
Zdravilo Ebilfumin se uporablja pri odraslih, mladostnikih, otrocih in dojenčkih (vključno z donošenimi novorojenčki) za zdravljenje gripe (influence).
Ebixa 10 mg film-coated tablets are presented as pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings ‘1 0’ on one side and ‘M M’ on the other side.
Ebixa 10 mg filmsko obložene tablete so bledo rumene do rumene, ovalne, z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in vtisnjeno besedo "M M" na drugi strani.
Ebixa 15 mg film-coated tablets are presented as orange to grey-orange, oval-oblong with imprint ‘15’ on one side and imprint ‘MEM’ on the other side.
Ebixa 15 mg filmsko obložene tablete so oranžne do sivo oranžne, ovalno podolgovate, z vtisnjeno številko "15" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Ebixa 20 mg film-coated tablets are presented as are pale red to grey-red, oval-oblong with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Ebixa 20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno podolgovate, z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Ebixa 20 mg film-coated tablets.
Ebixa 20 mg filmsko obložene tablete
Ebixa 5 mg
Ebixa 5 mg memantinijev klorid
Ebixa 5 mg film-coated tablets are presented as white to off-white, oval-oblong with imprint ‘5’ on one side and imprint ‘MEM’ on the other side.
Ebixa 5 mg filmsko obložene tablete so bele do belkaste, ovalno podolgovate, z vtisnjeno številko "5" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Ebixa 5 mg film-coated tablets Ebixa 10 mg film-coated tablets Ebixa 15 mg film-coated tablets Ebixa 20 mg film-coated tablets Memantine hydrochloride
Ebixa 5 mg filmsko obložene tablete Ebixa 10 mg filmsko obložene tablete Ebixa 15 mg filmsko obložene tablete Ebixa 20 mg filmsko obložene tablete memantinijev klorid
Ebixa 5 mg/pump actuation oral solution
Ebixa 5 mg/pritisk raztopina
Ebixa 5 mg/pump actuation oral solution memantine hydrochloride
Ebixa 5 mg/pritisk peroralna raztopina memantinijev klorid
Ebixa 5 mg/pump actuation oral solution.
Ebixa 5 mg/pritisk peroralna raztopina
Ebixa acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Ebixa deluje na receptorje NMDA in izboljša prenos živčnih signalov in spomin.
Ebixa belongs to a group of medicines called NMDA- receptor antagonists.
Ebixa spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.
Ebixa film-coated tablets are presented as pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Ebixa filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno podolgovate, filmsko obložene tablete z vtisnjeno številko "20" na eni strani in besedo "MEM" na drugi strani.
Ebixa has been studied in three main studies including a total of 1,125 patients with Alzheimer’s disease, some of whom had taken other medicines for their disease in the past.
Zdravilo Ebixa so proučevali v treh glavnih študijah, ki so vključevale skupno 1 125 bolnikov z Alzheimerjevo boleznijo, pri čemer so nekateri izmed njih v preteklosti prejemali druga zdravila za zdravljenje te bolezni.
Ebixa is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Zdravilo Ebixa uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Ebixa is used to treat patients with moderate to severe Alzheimer’s disease.
Zdravilo Ebixa se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Ebixa memantine hydrochloride
Ebixa memantinijev klorid
Ebixa should be administered orally once a day and should be taken at the same time every day.
Zdravilo Ebixa je treba dati peroralno enkrat dnevno in ga je treba zaužiti ob istem času vsak dan.
Ebixa was more effective than placebo at controlling the symptoms of Alzheimer’s disease.
Zdravilo Ebixa je bilo pri nadzorovanju simptomov Alzheimerjeve bolezni učinkovitejše od placeba.
EBMT criteria g All randomised patients with secretory disease
zdravljenja. f CR = popolni odgovor; PR = delni odgovor, EBMT kriteriji g Vsi randomizirani bolniki s sekrecijsko boleznijo
EBR with GZR for 12 weeks (N = 312)
EBR z GZR 12 tednov (n = 312)
EBR/GZR for 12 or 16 weeks (N=105 and 105, respectively)
izključili oziroma prekinili njihovega
EBR/GZR for 12 weeks (N=218)
EBR/GZR 12 tednov (n = 218)
EBV associated lymphoproliferative disorder**,lung cancer, rectal cancer, breast cancer, sarcoma, kaposi's sarcoma, prostate cancer, cervix carcinoma, laryngeal cancer, lymphoma, multiple myeloma, transitional cell carcinoma
z virusom EBV povezana limfoproliferativna bolezen**, pljučni rak, rak danke, rak dojke, sarkom, Kaposijev sarkom, rak prostate, karcinom materničnega vratu, rak grla, limfom, multipli mielom, prehodnocelični karcinom
EBV seronegative patients receiving immunosuppressants are at a particularly increased risk for PTLD.
Pri EBV seronegativnih bolnikih, ki se zdravijo z imunosupresivnimi zdravili, je tveganje za razvoj PTLB še posebej veliko.
EBV-Viral Capsid Antigen (VCA)-negative patients have been reported to have an increased risk of developing lymphoproliferative disorders.
Poročali so, da pri EBV- VCA (antigen virusne kapside) negativnih bolnikih obstaja večje tveganje za razvoj limfoproliferativnih bolezni.
Ebymect 5 mg/1,000 mg are 10.5 x 21.5 mm oval, yellow film-coated tablets.
Zdravilo Ebymect 5 mg/1000 mg so 10,5 x 21,5 mm velike, ovalne, rumene filmsko obložene tablete.
Ebymect 5 mg/850 mg are 9.5 x 20 mm oval, brown film-coated tablets.
Zdravilo Ebymect 5 mg/850 mg so 9,5 x 20 mm velike, ovalne, rjave filmsko obložene tablete.
Ebymect can also be used to replace dapagliflozin and metformin taken as separate tablets.
Zdravilo Ebymect se lahko uporablja tudi namesto ločenih tablet dapagliflozina in metformina.
Ebymect combines two anti-hyperglycaemic medicinal products with different and complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Zdravilo Ebymect je kombinacija dveh antihiperglikemičnih učinkovin z različnima in komplementarnima mehanizmoma delovanja, ki izboljšata urejenost glikemije pri bolnikih s sladkorno boleznijo tipa 2: dapagliflozina, zaviralca natrij-glukoznega soprenašalca 2 (SGLT2 – sodium glucose co-transporter 2), in metforminijevega klorida, ki spada v skupino bigvanidov.
Ebymect contains two different active substances, which work in different ways:
Zdravilo Ebymect vsebuje dve različni zdravilni učinkovini, ki delujeta na različna načina:
Ebymect dapagliflozin / metformin
Ebymect dapagliflozin/metformin
Ebymect is a diabetes medicine that contains the active substances dapagliflozin and metformin.
Ebymect je zdravilo za sladkorno bolezen, ki vsebuje zdravilni učinkovini dapagliflozin in metformin.
Ebymect is available as tablets (5 mg dapagliflozin/850 mg metformin and 5 mg dapagliflozin/ 1,000 mg metformin) and can only be obtained with a prescription.
Zdravilo Ebymect je na voljo v obliki tablet (5 mg dapagliflozina/850 mg metformina in 5 mg dapagliflozina/1 000 mg metformina) in se izdaja le na recept.
ECALTA can be given without regard to the timing of haemodialysis (see section 5.2).
Zdravilo ECALTA lahko apliciramo ne glede na čas hemodialize (glejte poglavje 5.2).
ECALTA contains the active substance anidulafungin and is prescribed in adults to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis.
Zdravilo ECALTA vsebuje zdravilno učinkovino anidulafungin in se uporablja pri odraslih za zdravljenje posebne vrste glivične okužbe krvi ali drugih notranjih organov, imenovane invazivna kandidoza.
ECALTA has not been studied in patients with Candida endocarditis, osteomyelitis or meningitis.
Zdravila ECALTA niso proučevali pri bolnikov z endokarditisom, osteomielitisom ali meningitisom, povzročenimi s Candido.
ECALTA is not dialysable.
Zdravilo ECALTA se ne dializira.
ECALTA should be given to you once a day, by slow infusion (a drip) into your vein.
Zdravilo ECALTA morate dobiti enkrat na dan v počasni infuziji (kapalni) v veno.
ECALTA should not be given to patients under 18 years of age.
Zdravila ECALTA ne smejo dobiti bolniki, mlajši od 18 let.
ECALTA will always be prepared and given to you by a doctor or a healthcare professional (there is more information about the method of preparation at the end of the leaflet in the section for medical and healthcare professionals only).
Zdravilo ECALTA bo vedno pripravil in vam ga dal zdravnik ali zdravstveni delavec (več informacij o načinu priprave je na koncu tega navodila v poglavju, namenjenemu samo zdravstvenemu osebju).
Ecansya 150 mg film-coated tablets (tablets) are light peach coloured, oblong shaped, biconvex tablets of 11.4 mm in length and 5.3 mm in width, debossed with "150" on one side and plain on other side.
Ecansya 150 mg filmsko obložene tablete (tablete) so svetlo breskove barve, podolgovate oblike, bikonveksne, dolžine 11,4 mm in debeline 5,3 mm, z vtisnjeno oznako "150" na eni strani in brez oznake na drugi strani.
Ecansya 150 mg film-coated tablets Capecitabine
Ecansya 150 mg filmsko obložene tablete kapecitabin
Ecansya 150 mg film-coated tablets Ecansya 300 mg film-coated tablets Ecansya 500 mg film-coated tablets
Ecansya 150 mg filmsko obložene tablete Ecansya 300 mg filmsko obložene tablete Ecansya 500 mg filmsko obložene tablete
Ecansya 150 mg film-coated tablets Ecansya 300 mg film-coated tablets Ecansya 500 mg film-coated tablets Capecitabine
Ecansya 150 mg filmsko obložene tablete Ecansya 300 mg filmsko obložene tablete Ecansya 500 mg filmsko obložene tablete kapecitabin
Ecansya 300 mg film-coated tablets Capecitabine
Ecansya 300 mg filmsko obložene tablete kapecitabin
Ecansya 500 mg film-coated tablets are peach colored, oblong shaped, biconvex tablets of 15.9 mm in length and 8.4 mm in width, debossed with "500" on one side and plain on other side.
Ecansya 500 mg filmsko obložene tablete so bele ali kremne bele barve, podolgovate oblike, bikonveksne, dolžine 15,9 mm in debeline 8,4 mm, z vtisnjeno oznako "500" na eni strani in brez oznake na drugi strani.
Ecansya 500 mg film-coated tablets Capecitabine
Ecansya 500 mg filmsko obložene tablete kapecitabin
Ecansya can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Zdravilo Ecansya lahko izzove hude kožne reakcije, kot sta Stevens-Johnsonov sindrom in toksična epidermalna nekroliza.
Ecansya is a ‘generic’ and a ‘hybrid’ medicine.
Ecansya je „generično“ in „hibridno“ zdravilo.
Ecansya is indicated for the treatment of: for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1).
Zdravilo Ecansya je indicirano za: za adjuvantno zdravljenje bolnikov po operaciji raka kolona stadija III (Dukes C) (glejte poglavje 5.1).
Ecansya is not indicated in children and adolescents.
Zdravilo Ecansya ni namenjeno otrokom in mladostnikom.
Ecansya is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient’s height and weight).
Jemlje se dvakrat na dan v odmerkih med 625 in 1 250 mg na kvadratni meter telesne površine (izračunane na podlagi bolnikove višine in telesne mase).
Ecansya is used with or without other anticancer medicines in patients who have had surgery for ‘stage III’ or ‘Dukes’ stage C’ colon cancer; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Zdravilo Ecansya se uporablja z drugimi zdravili proti raku ali samostojno pri bolnikih po operaciji raka kolona stadija III ali stadija Dukes C; metastatskega kolorektalnega raka (raka debelega črevesa, ki se je razširil na druge dele telesa).
Ecansya is used with or without other anticancer medicines; advanced gastric (stomach) cancer.
Zdravilo Ecansya se uporablja z drugimi zdravili proti raku ali samostojno; napredovale oblike raka želodca.
Ecansya should only be prescribed by a qualified physician experienced in the utilisation of anti- neoplastic medicinal products.
Zdravilo Ecansya lahko predpiše le zdravnik z ustreznim znanjem in izkušnjami z uporabo zdravil za zdravljenje novotvorb.
Ecansya tablets should be swallowed with water within 30 minutes after a meal.
Tablete zdravila Ecansya je treba pogoltniti z vodo v 30 minutah po obroku.
Ecansya with food and drink
Zdravilo Ecansya skupaj s hrano in pijačo
Ecansya1 capecitabine
Ecansya1 kapecitabin
ecchymosis
bolečina
Ecchymosis
bolečina v okončini
Ecchymosis
ehkimoza
Ecchymosis
ekhimoza
ecchymosis (a small bruise caused by blood leaking from broken blood vessels in the skin)
ekhimoza (manjša podplutba zaradi uhajanja krvi iz poškodovanih žil v koži);
ecchymosis (a small bruise caused by blood leaking from broken blood vessels in the skin).
ekhimoza (manjša podplutba zaradi uhajanja krvi iz poškodovanih žil v koži);
ecchymosis (large skin hematoma)
ekhimoza (veliki kožni hematomi)
Ecchymosis or Swelling‡ at the injection site, injection-site rash‡
ekhimoza ali oteklina‡ na mestu injiciranja, izpuščaj na mestu injiciranja
Ecchymosis*
Ekhi- moza
Ecchymosis***
ekhimoze
Ecchymosis, bullous eruption, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema
ekhimoze, bulozen izpuščaj, eksfoliativni dermatitis, multiformni eritem, Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, angioede
Ecchymosis, bullous eruption, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema
ekhimoze, bulozen izpuščaj, eksfoliativni dermatitis, multiformni eritem, Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, angioedem
ecchymosis, pruritus
ehimoza, pruritus
Ecchymosis, Skin haemorrhage
ekhimoze, kožne krvavitve
ECF: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
ECF: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), cisplatin (60 mg/m2 v 2-urni infuziji dan vsake 3 tedne) in 5-FU (200 mg/m2 na dan v kontinuirani infuziji skozi centralni venski kateter);
ECF: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
ECF: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), cisplatin (60 mg/m2 v 2-urni infuziji dan vsake 3 tedne) in 5-FU (200 mg/m2 na dan v kontinuirani infuziji skozi centralni venski kateter);
ECG changes (such as a clinically meaningful sinus pause, complete heart block, new bundle branch block, significant prolongation of the QRS or QT interval, changes consistent with ischaemia or infarction and ventricular arrhythmia)
bradikardija spremembe EKG (npr. klinično pomembna sinusna pavza, kompletni srčni blok, nov kračni blok, pomembna razširitev kompleksa QRS ali podaljšanje intervala QT, spremembe, ki ustrezajo ishemiji ali infarktu, ali prekatne motnje srčnega ritma)
ECG monitoring should be performed in high-risk patients as clinically indicated.
Opazovanje z EKG mora biti izvajano pri bolnikih z visoko stopnjo tveganja.
ECG prolonged QT interval
podaljšanje intervala QT na EKG
ECG QT interval prolongation
Podaljšanje intervala QT
ECG QTc interval prolonged
podaljšanje intervala QTc
ECG within 24 hours to determine QTc prolongation.
EKG v 24 urah za ugotovitev podaljšanja QTc.
Echinococcosis represents a hazard for humans, and is a notifiable disease to the World Organisation for Animal Health (OIE).
Ehinokokoza predstavlja nevarnost za ljudi in je OIE (Svetovna Organizacija za Zdravje Živali) prijavljiva bolezen.
Echinococcus granulosus (mature adult and immature)
Echinococcus granulosus (zrela odrasla oblika in nezrela oblika)
Echinococcus multilocularis (mature adult and immature)
Echinococcus multilocularis (zrela odrasla oblika in nezrela oblika)
Echo- cardiogram abnormal
ehokar- diogra- fske nepravil nosti
Echocardiogram is recommended before initiation of INCRELEX treatment in all patients.
Pred začetkom zdravljenja z zdravilom INCRELEX je pri vseh bolnikih priporočljiva uporaba ehokardiograma.
Echocardiography revealed no indication of cardiac decompensation in a repeat dose safety pharmacology study in rats at a systemic exposure 1.4-fold greater than that achieved therapeutically.
ni pokazala nobenih znakov srčne dekompenzacije v študiji farmakološke varnosti večkratnih odmerkov pri podganah pri sistemski izpostavljenosti, ki je bila 1,4-krat večja od tiste, ki jo dosežemo pri terapiji.
Eckert & Ziegler EURO-PET Berlin GmbH, Germany
Eckert & Ziegler EURO-PET Berlin GmbH, Nemčija
Eclampsia and severe pre-eclampsia requiring delivery
eklampsija ali huda preeklampsija, ki zahtevata porod,
ECOG performance status, M stage, AJCC stage, gender, region and baseline LDH) might contribute to the clinical outcome.
M stadij, AJCC stadij, spol, regija in vrednost LDH v izhodišču) lahko prispevajo k kliničnemu izidu.
ECOG Performance Status, n (%)
Status zmogljivosti po ECOG, n (%)
ECOG Performance Status, n (%) 0
Indeks zmogljivosti ECOG, n (%) 0
ECOG=0 or 1
ECOG = 0 ali 1
econds
ekund sekund
Econor 10% 750 mg/kg feed
Econor 10 % 750 mg/kg krme
Econor 10% Hypromellose Talc
Econor 10 % Hipromeloza Smukec
Econor 10% mg Econor 10% premix/kg feed = Dosage required (mg/kg) x 10 x bodyweight (kg)/Daily feed intake (kg).
Econor 10 % mg Econor 10 % predmešanica/kg krme = priporočen odmerek (mg/kg) x 10 x telesna masa (kg)/količino dnevnega vnosa krme (kg)
Econor 10% oral powder for pigs
Econor 10 % peroralni prašek za prašiče
Econor 10% oral powder for pigs is available in 1 kg bags.
Econor 10 % peroralni prašek za prašiče je na voljo v 1 kg vrečkah.
Econor 10% oral powder for pigs Valnemulin
Econor 10 % peroralni prašek za prašiče Valnemulin
Econor 10% oral powder for pigs Valnemulin hydrochloride
Econor 10 % peroralni prašek za prašiče Valnemulinijev klorid
Econor 10% oralpowder (g)
Econor 10 % peroralni prašek (v g)
Econor 10% premix and Econor 10% oral powder
Econor 10 % predmešanica za pripravo zdravilne krmne mešanice in Econor 10 % peroralni prašek
Econor 10% premix contains valnemulin in the form of valnemulin hydrochloride.
Econor 10 % predmešanica vsebuje valnemulin v obliki valnemulinijevega klorida.
Econor 10% premix for medicated feed for pigs and rabbits
Econor 10 % predmešanica za pripravo zdravilne krmne mešanice za prašiče in kunce
Econor 10% premix for medicated feed for pigs and rabbits is available in 1 kg and 25 kg bags.
Econor 10 % predmešanica za pripravo zdravilne krmne mešanice za prašiče in kunce je na voljo v 1 kg in 25 kg vrečkah.
Econor 10% premix for medicated feed for pigs and rabbits Valnemulin
Econor 10 % predmešanica za pripravo zdravilne krmne mešanice za prašiče in kunce Valnemulin
Econor 10% premix for medicated feed for pigs and rabbits Valnemulin hydrochloride
Econor 10 % predmešanica za pripravo zdravilne krmne mešanice za prašiče in kunce Valnemulinijev klorid
Econor 50% 150 mg/kg feed
Econor 50 % 150 mg/kg krme
Econor 50% 50 mg/kg feed
Econor 50 % 50 mg/kg krme
Econor 50% Hypromellose Talc.
Econor 50 % Hipromeloza Smukec